Barry Snow described the results of the study as a "Rubiks Cube" where understanding how the results came about is a puzzle. That is what they are trying to do now, looking at all the characteristics of the individual patients and seeing if it has any relationship to the responses at a given dose. The longer the study time, the more data points they have, the better the chances they have of getting some insight.
Personally I don't believe they will pursue the PD use of NTcell if they cannot find some reasonable good scioentific evidence of efficacy in the data from the trial over 18-24 months. They would need to see a consistent trend which leads to statistical significance to seek and allocate more funds.
LCT Price at posting:
2.9¢ Sentiment: None Disclosure: Held
